Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

YolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing ...

The global Cell and Gene Therapy Market is valued at $20.5 billion in 2024 and is projected to reach a value of $128.8 ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Artificial intelligence is making waves across industries, but its impact is higher in some sectors than others. Medicine and other sciences stand to gain much from this technology, thanks to their ...

Decades ago, researchers showed that Down syndrome (also known as trisomy 21), was caused when individuals carried an extra ...